December 10, 2019
Novo Nordisk Pharma and MSD said on December 9 that they have entered into a sales collaboration pact to copromote the Danish diabetes powerhouse’s oral GLP-1 agent semaglutide in Japan. In Japan, once-daily oral semaglutide was filed in July this...read more